La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Ocugen Gestion

Gestion contrôle des critères 2/4

Le PDG Ocugen's est Shankar Musunuri, nommé en Sep2019, a un mandat de 4.42 ans. La rémunération annuelle totale est $ 7.66M, composée du salaire de 9.3% et des bonus 90.7%, y compris les actions et options de la société. détient directement 0.8% des actions de la société, d'une valeur de € 1.88M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.4 ans et 4.3 ans.

Informations clés

Shankar Musunuri

Directeur général

US$7.7m

Rémunération totale

Pourcentage du salaire du PDG	9.3%
Durée du mandat du directeur général	4.4yrs
Propriété du PDG	0.8%
Durée moyenne d'occupation des postes de direction	1.4yrs
Durée moyenne du mandat des membres du conseil d'administration	4.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Shankar Musunuri a-t-elle évolué par rapport aux bénéfices de Ocugen?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2023	n/a	n/a	-US$76m
Jun 30 2023	n/a	n/a	-US$83m
Mar 31 2023	n/a	n/a	-US$80m
Dec 31 2022	US$8m	US$715k	-US$81m
Sep 30 2022	n/a	n/a	-US$74m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$69m
Dec 31 2021	US$8m	US$541k	-US$58m
Sep 30 2021	n/a	n/a	-US$48m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$2m	US$500k	-US$34m
Jun 30 2020	n/a	n/a	-US$30m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$572k	US$420k	-US$20m
Sep 30 2019	n/a	n/a	-US$39m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$431k	US$420k	-US$18m

Rémunération vs marché: La rémunération totale de Shankar ($USD 7.66M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché BG ($USD 609.27K ).

Rémunération et revenus: La rémunération de Shankar a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Shankar Musunuri (59 yo)

4.4yrs

Titularisation

US$7,662,810

Compensation

Dr. Shankar Musunuri, Ph D., MBA, is the Co-Founder of Ocugen, Inc. and has been its Chairman and Chief Executive Officer and Director since September 27, 2019. He served as Interim Principal Financial Off...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Shankar Musunuri	Co-Founder	4.4yrs	US$7.66m	0.80% € 1.9m
Uday Kompella	Co-founder & Independent Director	no data	US$341.82k	0.27% € 643.6k
Michael Breininger	Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller	less than a year	pas de données	pas de données
Arun Upadhyay	Chief Scientific Officer and Head of Research & Development	1.4yrs	pas de données	0.041% € 95.4k
John Kouch	General Counsel	no data	pas de données	pas de données
Tiffany Hamilton	Head of Corporate Communications	no data	pas de données	pas de données
Michael Shine	Senior Vice President of Commercial	2.7yrs	pas de données	pas de données
Jyothy Pillai	Head of Regulatory & Quality	less than a year	pas de données	pas de données

1.4yrs

Durée moyenne de l'emploi

48.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 2H51 n'est pas considérée comme expérimentée (ancienneté moyenne 1.4 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Shankar Musunuri	Co-Founder	4.4yrs	US$7.66m	0.80% € 1.9m
Uday Kompella	Co-founder & Independent Director	4.4yrs	US$341.82k	0.27% € 643.6k
Prabhavathi Fernandes	Independent Director	3.8yrs	US$357.60k	0% € 0
Carl Regillo	Member of Retina Scientific Advisory Board	4.3yrs	pas de données	pas de données
Ramesh Kumar	Independent Director	4.4yrs	US$347.28k	0% € 0
David Boyer	Member of Retina Scientific Advisory Board	no data	pas de données	pas de données
Bruce Forrest	Vaccine Scientific Advisory Board Member	3.2yrs	pas de données	pas de données
Junge Zhang	Independent Director	4.4yrs	US$335.56k	0.45% € 1.1m
Geeta Lalwani	Member of Retina Scientific Advisory Board	no data	pas de données	pas de données
Kirsten Castillo	Independent Director	3.8yrs	US$348.18k	0.019% € 45.6k
Satishchandran Chandrasekhar	Vaccine Scientific Advisory Board Member	3.2yrs	pas de données	pas de données
Mark Pennesi	Member of Retina Scientific Advisory Board	4.3yrs	pas de données	pas de données

4.3yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 2H51 sont considérés comme expérimentés (ancienneté moyenne 4.3 ans).

Ocugen Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Business Advisory Board

Recent updates

Ocugen, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for Ocu200 Phase 1 Clinical Trial

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.

Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of OCU410 —A Novel Modifier Gene Therapy

Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400—First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication

Law Offices of Howard G. Smith Alleges Lawsuit Against Ocugen, Inc

Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. announced delayed 10-Q filing

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Ocugen, Inc. has completed a Follow-on Equity Offering.

No longer forecast to breakeven

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met

Forecast to breakeven in 2025

Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

High number of new directors

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology

Ocugen, Inc. Announces Board Changes

No longer forecast to breakeven

Ocugen, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Ocugen, Inc. Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2 18 in the Lancet Infectious Diseases

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin (Bbv152)

Forecast breakeven date pushed back to 2023

Ocugen, Inc. to Report Q1, 2022 Results on May 06, 2022

High number of new and inexperienced directors

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Ocugen, Inc. Announces Resignation of Sanjay S. Subramanian as Chief Financial Officer

Ocugen, Inc. Provides Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization Request

Forecast breakeven date pushed back to 2023

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million.

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N).

Ocugen, Inc. and Bharat Biotech Announce Results from a Study Conducted at Emory University

Ocugen, Inc. Announces COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety